Osteoporosis International

, Volume 23, Issue 1, pp 17–38

Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis

  • J. A. Knopp-Sihota
  • C. V. Newburn-Cook
  • J. Homik
  • G. G. Cummings
  • D. Voaklander


Vertebral collapse is a common fracture associated with osteoporosis. Subsequent pain may be severe and often requires medications and bed rest. Several studies have suggested the use of calcitonin for the treatment of fracture pain. We sought to determine the analgesic efficacy of calcitonin for acute and chronic pain of osteoporotic vertebral compression fractures (OVCF). We searched for randomized, placebo, and controlled trials that evaluated the analgesic efficacy of calcitonin for pain attributable to OVCFs. We performed meta-analyses to calculate standardized mean differences (SMDs) using a fixed or random effects model. The combined results from 13 trials (n = 589) determined that calcitonin significantly reduced the severity of acute pain in recent OVCFs. Pain at rest was reduced by week 1 [mean difference (MD) = −3.39, 95% confidence interval (CI) = −4.02 to −2.76), with continued improvement through 4 weeks. At week 4, the difference in pain scores with mobility was even greater (SMD = −5.99, 95% CI = −6.78 to −5.19). For patients with chronic pain, there was no statistical difference between groups while at rest; there was a small, statistically significant difference between groups while mobile at 6 months (SMD = 0.49, 95% CI = −0.85 to −0.13, p = 0.008). Side effects were mild, with enteric disturbances and flushing reported most frequently. Although calcitonin has proven efficacy in the management of acute back pain associated with a recent OVCF, there is no convincing evidence to support the use of calcitonin for chronic pain associated with older fractures of the same origin.


Back pain Calcitonin Osteoporosis Vertebral fractures 


  1. 1.
    Lorrain J, Paiement G, Chevrier N, Lalumiere G, Laflamme GH, Caron P, Fillion A (2003) Population demographics and socioeconomic impact of osteoporotic fractures in Canada. Menopause 10(3):228–234PubMedCrossRefGoogle Scholar
  2. 2.
    Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761–1767PubMedCrossRefGoogle Scholar
  3. 3.
    Holroyd C, Cooper C, Dennison E (2008) Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 22(5):671–685PubMedCrossRefGoogle Scholar
  4. 4.
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475PubMedCrossRefGoogle Scholar
  5. 5.
    Kim DH, Vaccaro AR (2006) Osteoporotic compression fractures of the spine: current options and considerations for treatment. Spine J 6(5):479–487PubMedCrossRefGoogle Scholar
  6. 6.
    Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Int Med 128(10):793–800PubMedGoogle Scholar
  7. 7.
    Lyritis GP, Mayasis B, Tsakalakos N, Lambropoulos A, Gazi S, Karachalios T, Tsekoura M, Yiatzides A (1989) The natural history of the osteoporotic vertebral fracture. Clin Rheumatol 8(Suppl 2):66–69PubMedCrossRefGoogle Scholar
  8. 8.
    O’Neill TW, Cockerill W, Matthis C, Raspe HH, Lunt M, Cooper C, Banzer D, Cannata JB, Naves M, Felsch B, Felsenberg D, Janott J, Johnell O, Kanis JA, Kragl G, Lopes Vaz A, Lyritis G, Masaryk P, Poor G, Reid DM, Reisinger W, Scheidt-Nave C, Stepan JJ, Todd CJ, Woolf AD, Reeve J, Silman AJ (2004) Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. Osteoporos Int 15(9):760–765PubMedCrossRefGoogle Scholar
  9. 9.
    Cooper C, Atkinson EJ, O’Fallon WM, Melton LJ 3rd (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 7(2):221–227PubMedCrossRefGoogle Scholar
  10. 10.
    Francis RM, Aspray TJ, Hide G, Sutcliffe AM, Wilkinson P (2008) Back pain in osteoporotic vertebral fractures. Osteoporos Int 19(7):895–903PubMedCrossRefGoogle Scholar
  11. 11.
    Papaioannou A, Kennedy CC, Ioannidis G, Sawka A, Hopman WM, Pickard L, Brown JP, Josse RG, Kaiser S, Anastassiades T, Goltzman D, Papadimitropoulos M, Tenenhouse A, Prior JC, Olszynski WP, Adachi JD (2009) The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 20(5):703–714PubMedCrossRefGoogle Scholar
  12. 12.
    Barber JB, Gibson SJ (2009) Treatment of chronic non-malignant pain in the elderly: safety considerations. Drug Saf 32(6):457–474PubMedCrossRefGoogle Scholar
  13. 13.
    Plosker GL, McTavish D (1996) Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 8(5):378–400PubMedCrossRefGoogle Scholar
  14. 14.
    Maksymowych WP (1998) Managing acute osteoporotic vertebral fractures with calcitonin. Can Fam Physician 44:2160–2166PubMedGoogle Scholar
  15. 15.
    Siminoski K, Josse RG, Bowyer M (1996) Calcitonin in the treatment of osteoporosis. CMAJ 155(7):962–965PubMedGoogle Scholar
  16. 16.
    Abellan Perez M, Bayina Garcia FJ, Calabozo M, Carpintero Benitez P, Figueroa Pedrosa M, Fernandez Crisostomo MC, Garcia Lopez A, Garcia Perez S, Mesa Ramos M, Paulino Tevar J, Rodriguez Perez M, Salazar Vallina JM, Valenzuela Castano A, Povedano Gomez J, Sanchez Trenado A (1995) Multicentric comparative study of synthetic salmon calcitonin nasally administered in the treatment of established postmenopausic osteoporosis. An Med Interna 12(1):12–16PubMedGoogle Scholar
  17. 17.
    Ljunghall S, Gardsell P, Johnell O, Larsson K, Lindh E, Obrant K, Sernbo I (1991) Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcif Tissue Int 49(1):17–19PubMedCrossRefGoogle Scholar
  18. 18.
    Chesnut CH 3rd, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L (2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 19(4):479–491PubMedCrossRefGoogle Scholar
  19. 19.
    Azria M (2002) Possible mechanisms of the analgesic action of calcitonin. Bone 30(Suppl 5):80S–83SPubMedCrossRefGoogle Scholar
  20. 20.
    Ofluoglu D, Akyuz G, Unay O, Kayhan O (2007) The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol 26(1):44–49PubMedCrossRefGoogle Scholar
  21. 21.
    Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH (2005) Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 16(10):1281–1290PubMedCrossRefGoogle Scholar
  22. 22.
    Higgins J, Green S (eds) (2009) Cochrane handbook for systematic reviews of interventions version 5.0.2 (updated September 2009)Google Scholar
  23. 23.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535PubMedCrossRefGoogle Scholar
  24. 24.
    Higgens JPT, Deeks JJ (2008) Chapter 7: selecting studies and collecting data. In: Higgins J, Green S (eds) Cochrane handbook for systematic reviews of interventions version 501. The Cochrane CollaborationGoogle Scholar
  25. 25.
    Higgens JPT, Altman DG (2008) Chapter 8: assessing risk of bias in included studies. In: Higgins J, Green S (eds) Cochrane handbook for systematic reviews of interventions version 501. The Cochrane CollaborationGoogle Scholar
  26. 26.
    Deeks JJ, Higgins JPT, Altman DG (2008) Chapter 9: analysing data and undertaking meta-analysis. In: Higgins J, Green S (eds) Cochrane handbook for systematic reviews of interventions version 501. The Cochrane CollaborationGoogle Scholar
  27. 27.
    Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH (2008) Chapter 12: interpreting results and drawing conclusions. In: Higgins J, Green S (eds) Cochrane handbook for systematic reviews of interventions version 501. The Cochrane CollaborationGoogle Scholar
  28. 28.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMedCrossRefGoogle Scholar
  29. 29.
    Review Manager (RevMan) program. 5.0 (2008) The Nordic Cochrane Centre, Copenhagen. The Cochrane CollaborationGoogle Scholar
  30. 30.
    De Aloysio D, Pansini F, Campobasso C, Zanotti L, Abbruzzese AD, Mauloni M, Bottiglioni F (1996) Effects of cyclic therapy with intranasal carbocalcitonin in healthy spontaneous postmenopausal women. Clin Exp Obstet Gynecol 23(2):87–93PubMedGoogle Scholar
  31. 31.
    Dursun N, Dursun E, Yalcin S (2001) Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 55(8):505–509PubMedGoogle Scholar
  32. 32.
    Fidelis TS, Latorre LC, Resende C, Zerbini CA (1987) Effect of the combined therapy in the treatment of osteoporosis: observations on the use of salmon calcitonin. Rev Bras Reumatol 27(3):79–86Google Scholar
  33. 33.
    Foti R, Martorana U, Broggini M (1995) Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr Ther Res 56(5):429–435CrossRefGoogle Scholar
  34. 34.
    Gnudi S, Maggi G, Figus E, Rimondi E, Olmi R, Vellani G, Busacchi CA (1986) Efficacy of calcitonin in the symptomatic control of chronic backache due to senile osteoporosis. Clin Ter 118(2):119–124PubMedGoogle Scholar
  35. 35.
    Hernandez-Cassis C, Cure-Cure C, Hernandez-Cassis S, Latorre A, Cure J, Crespo S, Perez O, Arevalo O (1985) Uso de la calitonina en el tratamiento multifactorial de la osteoporosis. Salud Uninorte 2(1):3–12Google Scholar
  36. 36.
    Isaia GC, Di Stefano M, Sciolla A, Mussetta M, Vassellatti D (1995) Synthetic salmon calcitonin suppositories for the short-term treatment of involutive osteoporosis. Minerva Med 86(3):101–104PubMedGoogle Scholar
  37. 37.
    Konno S, Kikuchi S (2005) Therapeutic effects of calcitonin on back pain in the patients with osteoporosis. Clin Calcium 15(3):168–173PubMedGoogle Scholar
  38. 38.
    Tolino A, Romano L, Ronsini S, Riccio S, Montemagno U (1993) Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns. Int J Clin Pharmacol Ther Toxicol 31(7):358–360PubMedGoogle Scholar
  39. 39.
    Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, Tobinaga M, Hasegawa N, Kamae S, Yoshizawa M (2005) Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J Bone Miner Metab 23(2):167–173PubMedCrossRefGoogle Scholar
  40. 40.
    Dilsen G, Sindel D, An C (1996) Effect of nasal calcitonin on pain in osteoporotic patients with vertebral fractures. Osteoporos Int 6(Suppl 1):259CrossRefGoogle Scholar
  41. 41.
    Kopaliani M (2005) Effectiveness of intranasal salmon calcitonin treatment in postmenopausal osteoporosis. Georgian Med News 121:38–42PubMedGoogle Scholar
  42. 42.
    Orimo H, Fujita T, Yoshikawa S, Inoue T, Morita R (1994) Clinical study of SMC-20-051 nasal spray in pain due to osteoporosis. Clin Eval 22:211–231Google Scholar
  43. 43.
    Orimo H, Fujita T, Yoshikawa S, Inoue T, Morita R (1994) Clinical study of SMC-20-051 nasal spray in pain due to osteoporosis. Clin Eval 22:233–258Google Scholar
  44. 44.
    Ringe JD (1990) Treatment of primary osteoporosis with calcium and salmon calcitonin. Dtsch Med Wochenschr 115(31–32):1176–1182PubMedCrossRefGoogle Scholar
  45. 45.
    Szucs J, Horvath C, Kollin E, Szathmari M, Hollo I (1992) Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine. Calcif Tissue Int 50(1):7–10PubMedCrossRefGoogle Scholar
  46. 46.
    Vinceneux P, Pouchot J (1989) Analgesic effect of salmon calcitonin in crush vertebral fractures: double blind versus placebo study in 58 patients. Colombes, FranceGoogle Scholar
  47. 47.
    Watanabe M (1986) Clinical efficacy of YM-11221 (synthetic salmon calcitonin) for back or low back pain in osteoporosis: a double blind dose finding study. Clin Rep 20(13):6831–6844Google Scholar
  48. 48.
    Zhong J, Zhou YR, Lui SQ (2005) Interventional effects of salmon calcitonin on the bone metabolism, fracture healing and low back pain elderly patients with osteoporotic vertebral fracture. Chin J Rehab 9(27):156–157Google Scholar
  49. 49.
    Bertolini G, Naliato P, Cruciatti A, Geatti O, Perraro F (1982) Treatment of senile and postmenopausal osteoporosis with synthetic calcitonin. Med Geriatr 14(1):17–31Google Scholar
  50. 50.
    Covarrubias Cobos A, Javier Escalante F (1986) Clinical experience in the treatment of osteoporosis with synthetic salmon calcitocine. Invest Med Int 13(4):206–212Google Scholar
  51. 51.
    De Pascalis MA, Fletzer DA, Spirito A (1983) Clinico-statistical study in patients with an arthrosis–osteoporosis picture in its painful stage treated with synthetic salmon calcitonin. Clin Ter 107(3):177–184PubMedGoogle Scholar
  52. 52.
    Devogelaer JP, Azria M, Attinger M, Abbiati G, Castiglioni C, Nagant de Deuxchaisnes C (1994) Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue. Calcif Tissue Int 55(1):71–73PubMedCrossRefGoogle Scholar
  53. 53.
    Gonnelli S, Agnusdei D, Camporeale A, Palmieri R, Gennari C (1993) Effect of rectal salmon calcitonin treatment on bone mass and bone turnover in patients with established postmenopausal osteoporosis: a 1-year crossover study. Curr Ther Res Clin Exp 54(4):458–465CrossRefGoogle Scholar
  54. 54.
    Mannarini M, Fincato G, Galimberti S, Maderna M, Greco F (1994) Analgesic effect of salmon calcitonin suppositories in patients with bone pain. Curr Ther Res 55(9):1079–1083CrossRefGoogle Scholar
  55. 55.
    Alcala O (1986) An evaluation of therapeutic efficiency of synthetic salmon calcitonine in osteoporosis. Invest Med Int 13(3):189–192Google Scholar
  56. 56.
    Combe B, Cohen C, Aubin F (1997) Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int 61(1):10–15PubMedCrossRefGoogle Scholar
  57. 57.
    Kapuscinski P, Talalaj M, Borowicz J, Marcinowska-Suchowierska E, Brzozowski R (1996) An analgesic effect of synthetic human calcitonin in patients with primary osteoporosis. Mater Med Pol 28(3):83–86PubMedGoogle Scholar
  58. 58.
    Laroche M, Cantogrel S, Jamard B, Constantin A, Zabraniecki L, Cantagrel A, Mazieres B (2006) Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. Clin Rheumatol 25(5):683–686PubMedCrossRefGoogle Scholar
  59. 59.
    Lauro R, Palmieri G (1993) Effect of s-calcitonin on pain related to recent osteoporotic vertebral fractures: a single-blind controlled clinical study against ipriflavone. Acta Toxicologica et Therapeutica 14(2):73–83Google Scholar
  60. 60.
    Maresca V (1985) Human calcitonin in the management of osteoporosis: a multicentre study. J Int Med Res 13(6):311–316PubMedGoogle Scholar
  61. 61.
    Cisneros Dreinhoffer F, Mendez Huerta JV (1991) [Vertebral body compression fractures in the elderly female. A combination of conservative arthotic treatment and calcitonin-calcium administration]. Rev Mex Ortop Traumatol 5(2):58–61Google Scholar
  62. 62.
    Kelly Mexia L, Gonzalez Ibanez J (1988) Effectiveness of synthetic salmon calcitonin in the osteoporosis of the spine. Compend Invest Clin Latinoam 8(2):23–31Google Scholar
  63. 63.
    Yabur JA (1989) Postmenopausal osteoporosis: long time therapy with calcitonin and calcium. Arch Venez Farmacol Ter 8(1):51–55Google Scholar
  64. 64.
    Gennari C, Agnusdei D, Camporeale A (1991) Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 49(Suppl 2):S9–S13PubMedCrossRefGoogle Scholar
  65. 65.
    Lyritis GP, Trovas G (2002) Analgesic effects of calcitonin. Bone 30(Suppl 5):71S–74SPubMedCrossRefGoogle Scholar
  66. 66.
    Mehta NM, Malootian A, Gilligan JP (2003) Calcitonin for osteoporosis and bone pain. Curr Pharm Des 9(32):2659–2676PubMedCrossRefGoogle Scholar
  67. 67.
    Attali G, Levernieux L, Caulin F (1987) Recent crush fracture syndrome. Effect of salmon calcitonin. Results of three double blind studies and one open study. In: Christiansen C, Johanson JS, Riis BJ (eds) Osteoporosis 1987/International Symposium on Osteoporosis. Osteopress, Copenhagen, pp 930–932Google Scholar
  68. 68.
    Bordier Ph, Julien D, Caulin F (1986) Effects of a calcitonin treatment on bone pain and resorption parameters due to recent vertebral compression fracture. Results of a double blind and opened study. Rhumatologie 38(7):215–221Google Scholar
  69. 69.
    Rifat SF, Kiningham RB, Peggs JF (1992) Calcitonin in the treatment of osteoporotic bone pain. J Fam Pract 35(1):93–96PubMedGoogle Scholar
  70. 70.
    Medeiros Magliano MF, Monteiro Zilenovski A (1988) Treatment of senile osteoporosis with salmon calcitonin: results of a multicentric short-term study; evaluation of epidemiologic data. Arq Bras Med 62(4):297–308Google Scholar
  71. 71.
    Arinoviche R, Arriagada M, Jacobelli S, Massardo L, Rivero S, Aris H, Valenzuela M, Rojas C, Carvallo A, Gatica H et al (1987) Calcitonin in acute pain due to vertebral fracture in osteoporosis. Cooperative study. Rev Med Chil 115(11):1039–1043PubMedGoogle Scholar
  72. 72.
    Levernieux J, Bordier P, Julien D, Caulin F (1985) The effect of calcitonin on bone pain and acute resorption related to recent osteoporotic fractures. Result of a double blind and open study. In: Cecchettin M, Segre G (eds) 5th International Congress on Calciotropic Hormones and Calcium Metabolism. Elsevier Science Publishers (Biomedical Division), Venice, pp 171–178Google Scholar
  73. 73.
    Lyritis GP, Ioannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaioannou N, Kaloudis J, Galanos A (1999) Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 15(4):284–289PubMedCrossRefGoogle Scholar
  74. 74.
    Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG (1997) Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand 68(275):112–114Google Scholar
  75. 75.
    Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M (1991) Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 49(6):369–372PubMedCrossRefGoogle Scholar
  76. 76.
    Pun KK, Chan LW (1989) Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 11(2):205–209PubMedGoogle Scholar
  77. 77.
    Consoli V, Alfieri P, Giuntini C, Mancia M, Avaldi F, Soncini R (1991) A double blind placebo-controlled trial of the efficacy and tolerability of intranasal elcatonin administered to patients suffering from senile and postmenopausal osteoporosis. Curr Ther Res 50(3):369–378Google Scholar
  78. 78.
    Papadokostakis G, Damilakis J, Mantzouranis E, Katonis P, Hadjipavlou A (2006) The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis. Eur Spine J 15(3):356–362PubMedCrossRefGoogle Scholar
  79. 79.
    Peichl P, Rintelen B, Kumpan W, Broll H (1999) Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy. Gynecol Endocrinol 13(1):7–14PubMedCrossRefGoogle Scholar
  80. 80.
    Pontiroli AE, Pajetta E, Scaglia L, Rubinacci A, Resmini G, Arrigoni M, Pozza G (1994) Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study. Aging (Milano) 6(6):459–463Google Scholar
  81. 81.
    Szejnfeld VL, Ferraz MB, Sato EI, Atra E (1991) Analgesic effect of salmon calcitonin in patients with osteoporosis: randomized double blind method. Rev Bras Ortop 26(3):81–85Google Scholar
  82. 82.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101PubMedCrossRefGoogle Scholar
  83. 83.
    Myles PS, Troedel S, Boquest M, Reeves M (1999) The pain visual analog scale: is it linear or nonlinear? Anesth Analg 89(6):1517–1520PubMedGoogle Scholar
  84. 84.
    Todd KH, Funk KG, Funk JP, Bonacci R (1996) Clinical significance of reported changes in pain severity. Ann Emerg Med 27(4):485–489PubMedCrossRefGoogle Scholar
  85. 85.
    Overgaard K, Agnusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C (1991) Dose–response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 72(2):344–349PubMedCrossRefGoogle Scholar
  86. 86.
    LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F (1997) Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 337(8):536–542PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Authors and Affiliations

  • J. A. Knopp-Sihota
    • 1
  • C. V. Newburn-Cook
    • 2
  • J. Homik
    • 3
  • G. G. Cummings
    • 4
  • D. Voaklander
    • 5
  1. 1.Centre for Nursing and Health Studies, Faculty of Health DisciplinesAthabasca UniversityAthabascaCanada
  2. 2.Faculty of NursingUniversity of AlbertaEdmontonCanada
  3. 3.Department of MedicineUniversity of AlbertaEdmontonCanada
  4. 4.Faculty of NursingUniversity of AlbertaEdmontonCanada
  5. 5.School of Public HealthUniversity of AlbertaEdmontonCanada

Personalised recommendations